[go: up one dir, main page]

MX2017013360A - Methods for treating cancer. - Google Patents

Methods for treating cancer.

Info

Publication number
MX2017013360A
MX2017013360A MX2017013360A MX2017013360A MX2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
MX2017013360A
Other languages
Spanish (es)
Inventor
J Li Chiang
Li Youzhi
Gao Yuan
Li Wei
J Hitron Matthew
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of MX2017013360A publication Critical patent/MX2017013360A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I).
MX2017013360A 2015-04-17 2016-04-18 Methods for treating cancer. MX2017013360A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2017013360A true MX2017013360A (en) 2018-08-01

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013360A MX2017013360A (en) 2015-04-17 2016-04-18 Methods for treating cancer.

Country Status (16)

Country Link
US (1) US20180085341A1 (en)
EP (1) EP3283069A1 (en)
JP (1) JP2018511643A (en)
KR (1) KR20180006918A (en)
CN (1) CN107666906A (en)
AU (1) AU2016247319A1 (en)
BR (1) BR112017022281A2 (en)
CA (1) CA2983010A1 (en)
EA (1) EA201792287A1 (en)
HK (1) HK1250944A1 (en)
IL (1) IL255022A0 (en)
MX (1) MX2017013360A (en)
PH (1) PH12017501879A1 (en)
SG (2) SG10201900564WA (en)
TW (1) TW201713327A (en)
WO (1) WO2016168856A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745278B2 (en) 2007-09-10 2017-08-29 Boston Biomedical, Inc. Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
KR20150139955A (en) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer
EP3405189A1 (en) * 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer
JP7106563B2 (en) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Naphthofuran derivatives, their preparation and methods of use
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
WO2019050924A1 (en) * 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. New combination solution for treating chemotherapy refractory cancer
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
TW202102207A (en) * 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 Biomarker with therapeutic implications for carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745278B2 (en) * 2007-09-10 2017-08-29 Boston Biomedical, Inc. Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
MX370721B (en) 2010-03-19 2019-12-20 Boston Biomedical Inc Star Novel compounds and compositions for targeting cancer stem cells.
RU2591823C2 (en) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Novel methods for targeting cancer stem cells
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
KR20150139955A (en) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer
EP3405189A1 (en) * 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
AU2016247319A1 (en) 2017-11-02
IL255022A0 (en) 2017-12-31
KR20180006918A (en) 2018-01-19
WO2016168856A1 (en) 2016-10-20
US20180085341A1 (en) 2018-03-29
EP3283069A1 (en) 2018-02-21
EA201792287A1 (en) 2018-03-30
TW201713327A (en) 2017-04-16
HK1250944A1 (en) 2019-01-18
SG10201900564WA (en) 2019-02-27
SG11201708504XA (en) 2017-11-29
PH12017501879A1 (en) 2018-03-05
JP2018511643A (en) 2018-04-26
CA2983010A1 (en) 2016-10-20
BR112017022281A2 (en) 2018-07-10
CN107666906A (en) 2018-02-06

Similar Documents

Publication Publication Date Title
PH12017501879A1 (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX394380B (en) Cyclic dinucleotide compounds for cancer treatment
MX379270B (en) COMPOSITIONS INCLUDING BACTERIAL STRAINS.
IL253979B (en) Methods, compositions, and kits for treatment of cancer
HK1258098A1 (en) Methods of treating cancer
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
UA123201C2 (en) METHOD FOR PREPARATION OF DIARYLTHYOHYDRANTINE COMPOUND
MX2021006326A (en) Pcna inhibitors.
MX2016009663A (en) Icariin derivatives.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MX2018000715A (en) Methods for treating cancer using apilimod.
MX379271B (en) Compounds for treatment of cancer
MX382904B (en) DRUG COMBINATIONS FOR TREATMENT OF MULTIPLE MYELOMA.
JO3541B1 (en) Medical treatments based on anamorelin
PH12017501880A1 (en) Methods for treating cancer
MX388409B (en) COMPOSITIONS AND METHODS FOR TREATING CANCERS.
MX2015013021A (en) 5-bromo-indirubins.
MX390571B (en) METHODS FOR TREATMENT OF OVARIAN CANCER.
ZA201808381B (en) Methods and compositions for treating advanced stage non-small cell lung cancer
EA201992557A1 (en) ANTITUMOR COMPOUNDS
EA201892712A1 (en) METHODS FOR TREATING OVARIAN CANCER
AU2016902922A0 (en) Methods of Treating Cancer (I)